Project Grant HT9425261E367

The University of Florida Division of Sponsored Research received a $140,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective August 1, 2026 through July 31, 2028. The award supports the development of subtype-specific preclinical models for translational angiosarcoma research, conducted at the University of Florida's Gainesville campus. This research aligns with the DHA's mission to advance biomedical solutions addressing Service Member health and rare disease conditions; the award period of two years is typical for investigator-initiated research within this program, which generally supports project durations of three to four years with funding ranging from $100,000 to $20 million depending on scope and priority.

The funded research will generate preclinical disease models tailored to distinct angiosarcoma subtypes, enabling enhanced translational research pathways to advance therapeutic development and clinical applications. As a Project Grant (the predominant assistance type within CFDA 12.420, comprising 88 percent of program awards), this award provides direct support for discrete research activities without the collaborative infrastructure of a cooperative agreement, positioning the University of Florida as the prime recipient responsible for completing the specified research objectives over the two-year performance period.